Form 4: Acumen COO Sells Shares for Tax Obligations

Acumen Pharmaceuticals' Chief Operating Officer, Russell Barton, sold 3,530 shares of common stock to cover tax withholding obligations.

Summary

• Russell Barton, Chief Operating Officer of Acumen Pharmaceuticals, Inc. (ABOS), sold 3,530 shares of common stock.
• The transaction occurred on January 8, 2026, at a weighted average price of $1.8588 per share, with prices ranging from $1.8000 to $1.9500.
• The sale was an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
• This transaction was executed under a Rule 10b5-1 trading plan adopted by Mr. Barton on June 25, 2025.
• Following the sale, Mr. Barton beneficially owns 123,269 shares of Acumen Pharmaceuticals common stock directly.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine 'sell to cover' for tax purposes under a pre-arranged plan, which is a common and expected event for executives and does not indicate a change in company fundamentals or management's long-term view.

Positives

• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and not opportunistic sale.

Negatives

• An insider sale, even for tax purposes, reduces the officer's direct ownership in the company.

Industry Context

This is a routine insider transaction for tax purposes and does not inherently reflect on broader industry trends or competitive landscape for Acumen Pharmaceuticals. Such 'sell to cover' transactions are common for executives receiving equity compensation.

Stakeholder Impact

• Shareholders may note a slight reduction in direct insider ownership, but the pre-planned nature for tax purposes typically mitigates concerns about management's confidence.

Key Dates

Recommendation

The transaction is a routine 'sell to cover' for tax obligations under a pre-existing 10b5-1 plan. It does not signal a change in the company's fundamentals or management's outlook, thus a 'hold' recommendation is appropriate as this event alone does not warrant a change in investment thesis.

Keywords

Acumen Pharmaceuticals, ABOS, Russell Barton, Insider Trading, Form 4, Stock Sale, COO, Restricted Stock Units, Tax Withholding, 10b5-1 Plan